Good day, and welcome to the Assure Holdings First Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing star, then zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. Please also note this event is being recorded. Now, I would like to turn the conference over to Scott Kozak, Director of Investor Relations. Please go ahead.
Hello, everyone. Thank you for participating in today's conference call to discuss Assure Holdings financial results for the first quarter of 2022. On the call today are Executive Chairman and CEO, John Farlinger, and CFO, John Price. After market close this afternoon, the company issued a press release announcing its results for the first quarter 2022. The release and investor presentation are available on the investor section of our website. Before we begin the prepared remarks, I would like to remind you that some of the statements made will be forward-looking and are made under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected or implied due to a variety of factors.
We refer you to Assure's recent filings with the SEC, including our quarterly report on Form 10-K for the fourth quarter and full year for a more detailed discussion of the risks that could impact the company's future operating results and financial condition. Also in today's call, management will reference certain GAAP financial measures, which we believe provide useful information for investors. For a reconciliation of these non-GAAP measures, please consult the most recently filed 8-K associated with the filing of the earnings release for the three months ended March 31, 2022, which is available on the SEC website.
Finally, I would like to remind everyone who dialed in to the call by telephone, you may want to join our webcast or download our first quarter 2022 earnings presentation on Assure's investor relations site, found at ir.assureneuromonitoring.com, in order to see the slides referenced today. This call will be recorded and made available for replay via link on the company's website. Now, I would like to turn the call over to the Executive Chairman and CEO of Assure Holdings, John Farlinger. John.
Thank you, Scott. Hello, good afternoon, and thank you for joining us today. Today, we'll provide an update on our recent performance, the progress we've made against our strategic objectives, and discuss our vision for sustained rapid growth over the next several years. Select highlights include, firstly, record system-wide collections of $7.2 million, including a record $5.6 million from 100% owned Assure professional and technical entities in the first quarter. This was driven by accelerated collections of newer claims and out-of-network settlements on disputed claims. Secondly, the continued ramp of our higher-margin remote neurology services platform. Thirdly, our selection as contracted provider of intraoperative neuromonitoring services for two additional group purchasing organizations. Fourthly, adding a thirteenth state to our operational footprint. Lastly, we added several important new leadership hires that add important skills to experience in scaling emerging growth companies.
In 2022, we continue to expect 25,000+ managed procedures, an increase of more than 40% from 2021. During the first quarter of 2022, we did more than 5,100 procedures, an increase of more than 80% versus the prior year number of approximately 2,800 in Q1 of 2021. Next, on slide four and five, I will relay the current status of Assure's revenue cycle management function and our overall billing and collections efforts. There were some developments that we are really excited about, as well as some challenges faced by our revenue cycle management team. I will start with the challenges. Regretfully, Assure reported a reserve of $4.4 million in older receivables. Per longstanding company policy, these claims were automatically written down after reaching the 24-month threshold.
There is no excuse for these aged receivables to have not been worked in a timely and effective manner, and we are accountable for that. We've learned from this experience and set up a tactical team to specifically pursue these reserved claims. The company expects to begin seeing results from these collection efforts in the late second quarter, but significant traction during the second half of 2022. Given the ramp-up, we anticipate that there will be a bad debt charge in the second quarter. This will be smaller than what we experienced in the first quarter, but will still have a material impact. Net result will be that we expect EBITDA to be negative in Q2. The company expects Q3 EBITDA to be positive and Q4 to be very strong based upon our current forecast.
Ultimately, we expect to recover a meaningful share of cash receipts from these fully reserved receivables. I want to point out that the issue we are experiencing in 2022 is different from Assure's 2020 writedown. In 2020, the primary driver was a sharply lower accrual rate of net cash anticipated to be recovered from the cases we performed. Primary driver in 2022 is writing off reserves from an accounting standpoint because they have aged 24 months. We are confident that we will get to the issue from a cash collections perspective, and it will be resolved in the near term.
I wanna point out that Paul Webster, who's been with Assure since early 2019, has been promoted to the role of Senior Vice President and will oversee revenue cycle management and this team going forward. I wanna point out that Paul has been doing an outstanding job for us from a managed care perspective, overseeing Assure's in-network contracting and billing strategies with external payers. I'm confident the challenge with these aged receivables is an isolated issue that will not be repeated. We will not accept this going forward, and neither should you. Moving on to the next slides. While we are experiencing issue with aged accounts receivable, as you can see on slide five, we are also seeing a dramatic increase in current cash collections over a trailing six-, 12-, and 24-month period.
Assure achieved a record total collections of $7.2 million during the period, and record collections for 100%-owned Assure entities of $5.6 million in the quarter. Further, for accounts receivable generated from 100% Assure-owned entities, Assure is collecting approximately 65% in the first six months after they were issued, and 85% in the first twelve months after they were issued. Both of these are record rates for the company. Accelerating our cash flow reduces our need for working capital and also works to minimize reserves for the future. Taking a holistic look at the business, if you take our net revenue of $4.7 million and add back bad debt of $4.4 million, the revenue of the core business, excluding this charge, is approximately $9.1 million.
These accounting charges are not slowing down our belief that we will have a significantly strong second half of 2022. This includes our expectation of reporting positive adjusted EBITDA in full year 2022, anchored by strong revenue growth, managed case volume expansion, stable accrual rates, and our ramping remote neurology platform. Our goal is to become operationally cash flow and EBITDA positive on a full year basis. Slide six, I'll provide an update on our remote neurology business. As you recall, the 1-to-many model utilized for remote neurology services is where Assure is pivoting its business. To be clear, Assure neurologists are simply servicing the patient volume we already have established through the managed cases that our technologists perform. The focus now is simply transitioning Assure's patients onto our remote neurology platform.
As you can see in this chart, we are ramping our remote neurology services rapidly and anticipate performing more than 10,000 cases in 2022. Remote neurology is higher margin than our technologist services with receivables that are typically collected with much less friction. The reason Assure's telehealth remote neurology offering is one of the company's most important growth opportunities is because it is higher margin than our technologist services with receivables that are typically collected at an accelerated rate. Next, on to slide seven, you will see our geographic footprint. States in green represent our current operations, and those in yellow are locations that we are targeting. First quarter, we expanded to Minnesota, our thirteenth state, and anticipate meaningful growth potential in that market. Looking forward, the single most important catalyst for Assure's expansion is the winning of system-wide hospital facilities contracts.
Slide 8, we highlight our most important system-wide contracts to date. For a number of these, Assure serves as the sole contracted provider of intraoperative neuromonitoring services. The first and largest is with Premier. As we previously reported, Premier is the second-biggest group purchasing organization or GPO in the United States with an alliance of approximately 4,400 U.S. hospitals. In addition, last month, Assure was selected as the intraoperative neuromonitoring provider for two additional GPOs, Yankee Alliance and Conductiv. Yankee Alliance is a national healthcare GPO with over 18,500 members in all classes of trades. Conductiv membership includes 500 hospitals and surgery centers and more than 50 health systems. To add a bit more color on these GPOs, terms of these agreements were favorable from Assure's perspective. In addition, they provide us with a hunting license to pursue opportunities with their respective networks.
For Yankee Alliance, the pricing is entirely pre-negotiated for all their members. We believe this will facilitate more expeditious facility negotiations and implementations. Also, while Conductiv is affiliated with Premier, it includes a sizable number of members that are outside of Premier's network. This provides additional greenfield opportunities for Assure. Further, Conductiv and Yankee employ clinical experts who will work on Assure's behalf to help us gain access to the facilities in their network. These GPO agreements are consistent with our strategy to build a platform that enables hospitals and medical facilities to outsource intraoperative neuromonitoring services for thousands of procedures annually. On slide 9, I wanted to briefly introduce new talent added to Assure's management team. These individuals bring skills and experience that Assure did not have before and are poised to make a substantial positive impact on the organization.
Brian McDonald is our vice president of business operations, responsible for corporate strategy initiatives to drive growth and improve business performance. He will work to identify, analyze, and resolve business challenges and capitalize on new growth opportunities. Before joining Assure, Brian's experience included serving as Chief Financial Officer at Health Fidelity and Chief Operating Officer at Health Language prior to and following its acquisition by Wolters Kluwer Health. Kelly Shelton is our new Vice President of Sales, overseeing organic growth and channel strategy. Kelly has more than 25 years of experience as a sales leader in the healthcare industry. Most recently as Vice President at Zimmer Biomet Spine, where he led a team that generated more than $500 million in annual sales. Before that, Kelly was area vice president of Stryker Spine, where he grew strategic accounts and negotiated and closed numerous GPO contracts.
Sherri Wagner is our Vice President of Human Resources. Previously, Sherri held multiple HR roles at Fortune 250 organizations, including Amazon and Dish Network. Finally, James Watt was appointed to the position of National Technologist Director, ensuring quality of service and overseeing the company's training and development program. In addition, he will play an important role in the establishment of new competencies that will drive Assure's expansion into adjacent markets such as EEG, et cetera. James is highly experienced in the intraoperative neuromonitoring industry and maintains extensive relationships with surgeons and hospitals. Finally, on slide 10, I wanna highlight a few aspects of our ramp in managed cases. The first is the added scale in terms of managed procedures is critical from both an economies of scale and market share capture perspective. Second is the seasonality of our business.
We anticipate that the company's managed cases will follow the familiar pattern of a continued ramp up from the first quarter to a progressively busier second, third, and fourth quarters. Similarly, our revenue mix reflects the seasonality, with the first quarter typically representing our highest percentage of cases with patients utilizing government insurance. With each quarter after that, seeing the mix become progressively tilted toward more profitable commercial insurance. We anticipate both seasonality trends to continue in 2022. Before handing off to John Price, I want to emphasize our confidence and our belief that the opportunities ahead of us with remote neurology services, GPOs, organic expansion in new states, our channel program, and our commitment to clinical excellence will lead us to success both in the current year and in future years to come. Next, John Price will walk us through the quarterly financial information. John.
Thanks, John, and thank you everyone for joining us today. On slide eleven, I will provide color on financial results from our first quarter 2022. Assure continued to generate strong procedure growth, up 83% to more than 5,100 cases. However, Assure reported revenue of $4.7 million, adjusted EBITDA loss of $1.7 million, and net loss of $2.5 million. The previously mentioned reserve of aged receivables netted against current quarter revenue and negatively impacted our financial results.
Further, Q1 typically experiences seasonality due to less favorable revenue mix between government and commercial insurance, which reverses as the year progresses and case volumes increase. Our revenue accrual rate was stable from the fourth quarter to the first quarter, reinforcing our business fundamentals. Our operating expenses increased to $4.8 million compared to $3.8 million. The company's first quarter operating expenses primarily reflect headcount from growth in M&A. On slide 12, I will review Assure's balance sheet and cash flow. We ended Q1 2022 with $1.7 million in cash compared to $4 million at the end of 2021. Looking forward, we anticipate collections to improve in 2022, driven by our investment in automation, in-network contracting, and the benefit of our remote neurology billing.
The company's accounts receivable was $26.5 million, a sequential decrease of approximately $1.3 million from Q4 2021. As John mentioned, this was primarily due to the bad debt write-down, negating an increase in managed case volume and several million of accounts receivable from our remote neurology business. Despite the accounting charge, which we recognize consistent with the company's policy, we will continue to pursue collecting these aged receivables over the balance of 2022 and into 2023 and expect to be successful clawing back a meaningful portion of these reserve claims. The underlying health of the business remains strong, and we continuously look to streamline the business to run leaner and are committed to running much leaner in the second half of the year.
We anticipate the company will be adjusted EBITDA positive for full year 2022 and operating cash flow positive for the full year. With that, I'll turn the call back over to our operator for Q&A.
We'll now begin the question-and-answer session. To join the question queue, press star then one on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw yourself from the question queue, press star then two. We will pause momentarily to assemble our roster. The first question comes from Jim Sidoti with Sidoti & Co. Please go ahead.
Hi, good afternoon. Thanks for taking the question. So, you know, looking at the quarter, it seems like if you exclude the write-down, you had a quarter with record procedure, record sales, and record cash collections. Should I take from this that the pressure from COVID is at this point not nearly as significant and that, you know, some of your growth initiatives are starting to kick in?
Hey, Jim, it's John. Thanks for the question. You know, I think you've asked a couple of the questions there. Firstly, we're not gonna make any excuses on COVID. We're back to normal. We're not seeing any slowdown in any markets right now. There was a brief few weeks in January where we were affected, but no excuses. We're pretty much back to normal now on a business basis.
Okay. I guess the question was.
I think your other points are valid. You know, in terms of our model and our plan and our cadence for the year, we are pretty much almost exactly on our target of procedures, targeted revenue, and costs. Unfortunately, we took our eye off the ball a little bit on the RCM team. Certainly if you want more elaboration, we can talk about that. The issue here is some of this, a meaningful amount of this accounts receivable aged out over 24 months, and to be transparent, wasn't worked to the degree that we normally work our files. In fact, I think there was a race and a focus to get current AR worked, invoice collected, and we're doing that at a record pace.
Our eye was taken off the ball on some of this old AR. We've set up a tactical team to go after that old accounts receivable. Like we have in the past, a few years ago, we had a write-down over different reasons and much larger amounts, but we expect to collect a chunk of this AR. We're not gonna commit to how much, but we feel confident that there will be a meaningful amount of this AR collected over the balance of the year. I think the other point that I would make is that we see no reason to believe that we're not. You know, our guidance numbers are still pretty much our guidance numbers, and we're very confident that we're gonna move toward 25,000 procedures.
We're feeling very good, especially with the second half of the year and the opportunities are ahead of us right now, particularly the GPO contracts, the remote neurology business, and scaling this business. Don't know if that helps. I hope I answered your question there.
Yeah, you know, you've had write-downs in the past and you've been able to, you know, collect, you know, a significant portion of that, if that happens with these write-downs, will that just be applied to the revenue number and have the expenses already been accounted for?
These have been written off, so anything we collect on these old accounts receivable will be new revenue and income.
Okay. Can you talk about Premier? Have they been a meaningful contributor as yet, and has that helped improve your visibility, going forward?
Yeah. We're active. We're very active in the funnel on the Premier side. Some of you may have questions about. Tell us about Yankee and Conductiv and, you know, how do these pieces fit together. They're all separate entities that work within the Premier umbrella, in many cases, though, with different constituents. In the case of Conductiv, although it's a Premier-related company, it has different hospitals and different groups that we're able to gain access to. Part of our challenge right now is ramping up our sales team, and we've made a complete pivot on the sales team. We've brought in new leadership. We're continuing to bring in new leadership to drive revenue, and I expect that we'll be making announcements to that effect before the end of Q2. We've got a pretty good pipeline of opportunities now with Premier.
We're doing the same thing with Yankee. We're doing the same thing with Conductiv. We expect to be closing business in that network certainly in Q3, maybe earlier. We have a number of opportunities now that we're in negotiation on with respect to these facility agreements. I'm optimistic we're gonna get one or two of them over the line in the very near future, and we expect them to be contributors the second half of the year in terms of driving volume and scale. The other thing that I'll highlight is, you know, we went over the whole channel strategy in the past and how we can grow that business. We've got over 16 channel partners now working with us, and that's growing.
Again, in addition to our organic sales team, I think it's gonna have a meaningful impact on the second half of our year and 2023 going forward. You know, we're very bullish on what we're gonna do in the second half of the year.
All right. Now, on the expense side, Q1 is typically, you know, higher on the expense side for most companies, as they ramp up for the year. Were there any, what you would consider, you know, one-time charges in the quarter that you don't think will come into the remaining quarters of the year?
Yeah. Q1 is always a unique quarter in that on the revenue side we generate more of the Medicare, Medicaid cases. We get lower revenue. We have lower margin. That shifts with each subsequent quarter, cascading with a complete shift to the opposite direction by Q4. In Q1, you know, we had an inordinate number of one-time costs. The traditional costs, the audit, Nasdaq, a six-figure investment in software and other consulting fees. That as you look at Q2, Q3, Q4 in our model, we're actually reducing costs in Q2 with even lower costs in Q3, really in an attempt to become leaner over the course of the year. That's a stated objective of ours. We wanna run leaner. We believe we can run leaner, and we're running leaner right now as we unload costs.
I think as you look at. You know, I know a big issue here will be, will we run out of money? You know, we're flirting with being cash flow positive now. We're very close. If we wanna unwind some more costs, we can get really close to throwing off cash. Our goal is to run leaner going forward, and we will. So that's kind of where we're going right now. Q1 was an anomaly. John Price can probably give you the exact number of costs, but I'm gonna guess it was well over probably $500,000-$600,000 of one-time costs in Q1.
Jim, I have right around $800,000 of charges that we don't see really over the course of the year. As John indicated, it's really around the Nasdaq listing, which is upfront Q1, completion of our audit and ongoing, you know, some IT. We went live with a new system as well, HR system. All those costs attributed to increased expenses.
We made a significant investment in software that Paul Webster is utilizing that allows us to look at every state and to price the reimbursement rates so we can get a better predictive analysis of every market. There was a lot of one-time spending which really brought earnings down further, which won't be continued in Q2 and Q3.
As procedures grow, do you think you'll achieve positive free cash flow in the back half of 2022?
That's our expectation, yes.
Is there any reason?
To be clear and respectful. Go ahead.
I mean, there's no reason I think that would wouldn't not continue, you know, in 2023 and beyond, right?
Well, I think, you know, you look at the cash flow numbers in Q1 and the success we had, you know, it's being overshadowed by this writedown. If you look at the chart that we went through, we're collecting 65% of the amounts being billed in six-seven months, and 85% in 12 months. That's a radical shift from where we were 24 and 36 months ago. You see as we can continue to build that and scale it really reduces our need for working capital going forward. Ultimately, we feel very confident we're gonna be able to drive more business into a network contracting. The other thing that it does is as you get those types of numbers collected, it brings down your exposure to bad debt in the going forward.
The stuff, the bad debt that we're writing off now really relates to still some of the hangover of 2020 and finalizing that and getting it out of the way. You know, we're expecting a very strong Q2 in terms of cash collections, and we're in the middle of that right now. It's all about how do we speed up cash flow, how do we become better. I think as you saw those numbers, it was a radical shift in the cash which we're collecting, the rate at which we're collecting cash in Q1. You saw it starting in Q4, and we're very optimistic it's gonna continue for the rest of the year.
All right. The last one for me on the acquisition front, you know, that's been a big part of your story the last couple of years. I would imagine that, you know, valuations on the private side has come down just like valuations have for public companies. Are you seeing more opportunities? You know, are you at a point where you're ready to pull the trigger on another deal this year? Or do you think you're still digesting the two deals you did last year?
We've been active. We probably looked at no less, John, than what? three-four opportunities. We just. We haven't been able to get there on price. I think over the balance of the year, we'll continue to you know, we're not gonna do a deal simply to do one. We'll wait for the pricing and the rates to come back to us. Right now, you know, we haven't pulled the trigger on anything, but we're gonna be patient. That's our strategy, and we'll wait. Hopefully one of the deals will come back to us in terms of the pricing that we're looking for going forward.
Okay. All right. Thank you.
Again, if you'd like to join the question queue, press star then one. The next question comes from Bill Sutherland with The Benchmark Company. Please go ahead.
Thanks. Hey, everybody. Couple of questions. First, I wanted to understand a little better why the experience here with the bad debt from 24 months ago all kind of piled into this quarter. I would have thought it would be more of a sequential kind of
Yeah.
You know, hitting a 24-month trigger.
Paul, do you wanna maybe, since you did a lot of analysis on this, maybe give Bill a bit more of overview?
Sure.
as to why Q1, what happened, and really what are we doing about it now?
Sure. Bill, as you look at the aged receivables, we evaluate them in quarterly buckets.
Mm-hmm.
We start to look at reserves once it gets over a year. As those age over a year, we began a ramp-up reserve so that by the time we get to 24 months, we have some reserve against those accounts. We began evaluating accounts this way in Q4 of 2021 to make sure that we were appropriately reserving these accounts. Going into quarter one, as the AR moved across the one-year line, we had more reserve that we needed to look at. We expect based on you know what John talked about with acceleration of cash in current months in current quarters we expect that buildup to be significantly reduced once we move beyond Q2 of 2022.
Okay. That's the ongoing challenge, is the reserving process starting on month 13. What about the 24-month cliff? It seems like it would have happened again, not just with one reporting period.
Well, it was having to do with the particular quarters that we were evaluating as they aged. We're focused on 2020, and-
Q1 of 2020.
I'm sorry?
Q1 of 2020.
Yeah. Q1 of 2020.
Mm-hmm.
which was the one that dropped off, the 24 months. As we look at 2020 dates of service, including Q1, we're going after those, and we've built a task force. We've assigned, you know, an additional 10 individuals to go after those accounts. We have been focused on recouping accounts receivable that, as we focused on current accounts, we lost sight of. The Q1 bad debt was related to the movement of the queues going over the line. Does that make sense?
When you look at 2Q 2020, and when it crosses 24 months.
How do you kind of size that up? Well, we don't have a number yet because we're still working those accounts. We're not prepared to give you guidance in terms of the number on that at this point, because obviously we're focused on collecting that as much and quickly as we can. I think our position, though, Bill, as we look at it kind of subjectively, is each quarter will reduce from where we are now. Q2 will be lower than Q1. Q3, yet lower again. By Q4, we'll have worked all these claims. Just, you know, I don't wanna beat around the bush on your question.
The issue here is, you know, if there's a factor of 100 in terms of the work that's needed to be done in a quarter on a certain file, we did a fraction of that work on certain files in Q1 of 2020. We didn't realize the yield we want on some of those claims. It happened. We're not running from it. Now we've got a team of people that are set up to get to work, get that yield, and try to recover some of that money in Q2, Q3, Q4. Knowing that that happened, we've now got visibility into Q2, so we're working on those claims. Although this team is not gonna have probably the impact over 30 or 60 days, they will, though, be able to affect Q3 and certainly Q4 going after all this aged AR.
At the same time, we're having very good success on the front end in collecting and reducing our exposure going forward because at the rate we're collecting it, that reserve number is much lower in 2022, going into 2023 or 2024. All these things are happening at once. The reserve is dropping on current AR. We're collecting at record amounts. We've got the ball was dropped on the Q1 of 2020 AR, and we've gotta collect what we can on that and do the best we can to collect some of that cash. Just one more to clarify one more aspect of this. If for some reason you just let it sit, would the number be as big for the two Q bucket as one Q?
I mean, was it that? No. No, it's not. Oh, they weren't aging that bad. Okay. All right. No. Then to give me a perspective, this is the last one, I promise, on ARs. The perspective on the improvement in the aging and the collection rate versus like, where were you a year or two years ago versus where you are now with six months and 12 months? We probably have to give you an analysis of the days outstanding. We're gonna work to get that kind of into our Q2 analysis. Mm-hmm. Part of going forward is we wanna be able to show the market the days outstanding. Yeah. Clearly, you're seeing it just back of the envelope on the velocity of cash. You can see a progressive improvement here.
I think what we'll try to do is to show the velocity of cash. We wanna do two or three things in disclosure going forward, show the gross revenue less any write-offs, velocity of cash, and then days outstanding and aging of AR going forward. I think from our perspective, as we look at the balance of 2022, we'll see those days outstanding start to decline meaningfully going into Q4. Then by next year, you're gonna see a rapid decline because of the success we've had recently over the last few quarters on cash collections. Also, I think your in-network percentage will be much higher by year-end, right? Yeah. We're pretty. You know, we're not talking about that. Mm-hmm. But we're having some pretty good success.
The reason we're having some pretty good success settling these claims, much more than we had hoped from certain payers. I think it's gonna drive a conversation on a network contracting later in the year. Is this coming out of the No Surprises Act activity? Not yet. Okay. Well, we think there's upside to that as well. That'll simply be additional pressure on the payers, and Paul's working on that strategy right now. Mm-hmm. Okay. I think it's more of the tools. We're just getting better at doing it and how we can do it, and we're getting more settlements. Okay. The only number I was kind of scratching my head over in terms of just operations was remote neurology procedures. They were up quarter-over-quarter, just five or 6%, after you know being up huge.
Is that just a one-Q kind of phenomenon? Yeah, we're expecting a lift, you know, going into kind of Q3, Q4. You've got kind of a drop in volume from Q4 to Q1. Right. That's part of the equation here. Mm-hmm. Then you're trying to manage the Medicare/Medicaid claims and the commercial claims with an optimal return on that mix. Mm-hmm. We're still on track from our perspective to do 10,000 managed procedures this year. Okay. Last one, on the GPO, as you start to get these contracted, where is the pricing that you've kinda
Pre-negotiated or that you're expecting versus your standard pricing. Is it ballpark?
It's as good or better than what we're getting on average in our current pricing structure.
That's good. All right. That's all I got. Thanks, guys. Appreciate the color.
Thanks, Bill.
The next question comes from Brad Hemmingsen with Leede Jones Gable. Please go ahead.
John, in 2020, it was February that you took over Neuro-Pro, which was your first major acquisition, and that was also the same month that you took over billing completely from Clever Claims. Do you think that this lump of receivables that you had a hiccup on is related to maybe that big basket of accounts receivable you got on Neuro-Pro and taking over your revenue cycle management 100% then?
It's a component of it, Brad, but we're, you know, there were two or three things that happened. There was moving everything in-house. That happened at the same time. There was Clever Claims. There was Neuro-Pro, and there was an outside vendor that was being used by Neuro-Pro. All those factors enter into the discussion here, for us, and that's why one of the reasons why the Q1 numbers are a little higher than the Q2 numbers and the Q3 because Q2, we had kind of assimilated that data into our own billing team. They all enter into it, but, you know, we're not gonna use that as an excuse here. We went back. We've looked at the data. All those factors contributed to the write-down, but the reality is we could have.
There's a few things we could have done better, we're gonna do better, and we've got to get this remedy ASAP.
Okay. Thanks, John.
This concludes our question-and-answer session. I'll turn the conference back over to John for any closing remarks.
All right. Thank you. On behalf of the Assure team, we'd like to thank everyone for listening to today's call. Before concluding, I'd like to add a few last comments. Assure's greatest opportunities going forward include the following. Number one, expanding remote neurology services. Number two, taking full advantage of our position as the sole contracted provider of intraoperative neuromonitoring services for the Premier Network and related GPOs. three, organic growth that extends our reach within the existing states and helps us expand to new states, as well as leveraging more than 16 signed distributor agreements. Fourthly, utilizing data, analytics, and automation to strengthen revenue cycle management and to facilitate the signing of new in-network contracts. Fifthly and lastly, our desire to run leaner over the balance of 2022 as we move forward in our current business model. With that, I'm going to conclude.
We thank you all for your participation and your support, and we look forward to speaking to all of you again during our second quarter of 2022 call.
The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.